Recla, Juliana C.
HRN: 11-60-67 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/12/2024
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
02/12/2024
02/18/2024
IV
500mg
Q8
Amoebiasis
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes